Interstitial lung disease arising from erlotinib treatment in a Caucasian patient

Clin Lung Cancer. 2015 Mar;16(2):e1-3. doi: 10.1016/j.cllc.2014.11.003. Epub 2014 Nov 21.

Authors

Cristina Bugés¹, Enric Carcereny², Teresa Moran², Andrés Felipe Cardona³, Noemi Reguart⁴, Laia Capdevila⁵, Sara Cros⁶, Rafael Rosell²

Affiliations

¹ Catalan Institute of Oncology-Badalona, Barcelona, Spain. Electronic address: cbuges@iconcologia.net.
² Catalan Institute of Oncology-Badalona, Barcelona, Spain.
³ Clinical and Translational Oncology Group, Instituto de Oncología, Fundación Santa Fe de Bogotá, Colombia.
⁴ Hospital Clínic de Barcelona, Barcelona, Spain.
⁵ Hospital de Sant Pau i Santa Tecla, Tarragona, Spain.
⁶ Hospital General de Granollers, Barcelona, Spain.

PMID: 25550194
DOI: 10.1016/j.cllc.2014.11.003

No abstract available

Keywords: Corticosteroids; Erlotinib; Interstitial lung disease; Lung toxicity; TKI.

Publication types

Case Reports

MeSH terms

Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / pathology
ErbB Receptors / antagonists & inhibitors
ErbB Receptors / genetics
Erlotinib Hydrochloride
Humans
Lung Diseases, Interstitial / chemically induced*
Lung Neoplasms / drug therapy
Lung Neoplasms / pathology
Male
Middle Aged
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects*
Quinazolines / administration & dosage
Quinazolines / adverse effects*
White People

Substances

Protein Kinase Inhibitors
Quinazolines
Erlotinib Hydrochloride
ErbB Receptors